The Heart Rhythm Society (HRS) announced it would award up to $500,000 in grants for atrial fibrillation and stroke prevention research aimed at addressing National Quality Improvement priorities.

March 28, 2016—CHELMSFORD, MASS.—ZOLL® Medical Corporation, an Asahi Kasei Group Company that manufactures medical devices and related software solutions, announced today that its Japanese subsidiary, Asahi Kasei ZOLL Medical Corp. (AZM), has obtained approval from Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) to market the  company’s Thermogard XP™ (TGXP) Temperature Management System for sudden cardiac arrest in Japan.

Swedish researchers have found a way to use ultrasound to recognize plaque in the blood vessels and determine the risk of MI and stroke.

The Mobile Stroke Unit in Memphis, where stroke incidence is 37 percent higher than the national average, is the first launched in the high-incidence Southeastern United States “Stroke Belt”

PARSIPPANY, N.J., March 21, 2016 /PRNewswire-USNewswire/ -- Medinol is pleased to announce the enrollment of their first patient in the U.S. NIRTRAKS Study. NIRTRAKS is a post marketing, non-randomized study of the NIRxcell™ Stent System in patients with coronary artery disease indicated for PCI.  The study objective is to collect and analyze additional information about the safety and effectiveness of the NIRxcell stent in the treatment of de novo lesions in native coronary arteries in the U.S. population. 

STAMFORD, Conn.--(BUSINESS WIRE)--(Booth # 21076) – FUJIFILM Medical Systems U.S.A., Inc., will demonstrate the next generation of echocardiography, cardiac cath image management and structured reporting with the latest version of Synapse Cardiovascular at the American College of Cardiology (ACC) 65th Annual Scientific Session & Expo held April 2 – 4, 2016 at McCormick Place in Chicago, IL. The latest version provides a streamlined and efficient clinical experience for cardiologists and sonographers with new module enhancements.

IRVINE, Calif., March 16, 2016 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced that the Japanese Ministry of Health, Labor and Welfare (MHLW) approved the Edwards SAPIEN 3 transcatheter heart valve for the treatment of patients suffering from severe, symptomatic aortic stenosis.     

Royal Brompton Hospital, part of Royal Brompton & Harefield NHS Foundation Trust, has recently expanded its capability within the cardiac catheter lab, by opening a new state-of-the-art hybrid operating theatre for complex and combined cardiac procedures. An Artis Q zeego with PURE® technology from Siemens Healthcare is being used to assist with innovative cardiovascular procedures, including Transcatheter Aortic Valve Implantation (TAVI) and other aortic repairs.